Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to assess the efficacy and safety of the investigational
product SmofKabiven extra Nitrogen in patients requiring parenteral nutrition (PN) to achieve
the target protein dose. The cumulative target protein dose is 6.2 g per kg of body weight
(BW) over the five study treatment days, with 1.0 g/kg BW on Study Day 1 and 1.3 g/kg BW per
day on Study Days 2-5; the target caloric intake is 15 kcal/kg BW on Study Day 1 and 20
kcal/kg BW/day on Study Days 2-5, following the recommendation of the ESPEN guideline on
clinical nutrition in the intensive care unit 2019 regarding a slow-ramp up of calories
during the first week of critical illness.